Movatterモバイル変換

[0]ホーム

Jump to content

Lirilumab

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Lirilumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	KIR2DL1/2/3
Clinical data
ATC code	none
Identifiers
CAS Number	1000676-41-4
ChemSpider	none
UNII	S9XDI9W918
KEGG	D10444
Chemical and physical data
Formula	C₆₄₅₂H₉₉₁₈N₁₆₉₈O₂₀₃₀S₄₆
Molar mass	145228.93 g·mol⁻¹

Lirilumab (INN) is a humanmonoclonal antibody designed for the treatment of cancer.^[1]^[2] It binds toKIR2DL1/2/3.^[3]

This drug was developed by Innate Pharma and is licensed toBristol-Myers Squibb.

Clinical trials

[edit]

A phase 2 clinical trial foracute myeloid leukemia (AML)^[4] was terminated early ("failed") in 2017.^[5]

It was registered for a trial forsquamous cell carcinoma of the head and neck (SCCHN),^[6] but it may be abandoned.^[7]

As of November 2017^[update] nine clinical trials of lirilumab are registered as active.^[8]

References

[edit]

^World Health Organization (2012)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107"(PDF).WHO Drug Information.26 (2).
^Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab,American Medical Association.
^Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N (September 2009)."Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells".Blood.114 (13):2667–77.doi:10.1182/blood-2009-02-206532.PMC 2756126.PMID 19553639.
^Clinical trial numberNCT01687387 for "Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)" atClinicalTrials.gov
^Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017
^Clinical trial numberNCT03341936 for "Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck " atClinicalTrials.gov
^Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017
^lirilumab trials

Monoclonal antibodies for theimmune system

Immune system

Human	Immunosuppression:Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation:Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other:Bertilimumab Ontamalimab Zanolimumab Combination:Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive:Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation:Dostarlimab Other:Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatorylesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lirilumab&oldid=1228046651"

Categories:

Hidden categories:

[8]ページ先頭